Swiss National Bank’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-52,400
| Closed | -$5.34M | – | 2625 |
|
|
2023
Q2 | $5.34M | Sell |
52,400
-5,800
| -10% | -$549K | ﹤0.01% | 1273 |
|
|
2023
Q1 | $5.29M | Sell |
58,200
-6,600
| -10% | -$387K | ﹤0.01% | 1236 |
|
|
2022
Q4 | $2.46M | Buy |
64,800
+1,500
| +2% | +$51.6K | ﹤0.01% | 1764 |
|
|
2022
Q3 | $1.59M | Hold |
63,300
| – | – | ﹤0.01% | 2029 |
|
|
2022
Q2 | $1.92M | Hold |
63,300
| – | – | ﹤0.01% | 1938 |
|
|
2022
Q1 | $2.07M | Buy |
63,300
+4,400
| +7% | +$131K | ﹤0.01% | 2026 |
|
|
2021
Q4 | $1.55M | Hold |
58,900
| – | – | ﹤0.01% | 2218 |
|
|
2021
Q3 | $5.93M | Buy |
58,900
+700
| +1% | +$82.1K | ﹤0.01% | 1345 |
|
|
2021
Q2 | $8.24M | Buy |
58,200
+2,200
| +4% | +$248K | 0.01% | 1141 |
|
|
2021
Q1 | $5.58M | Buy |
56,000
+1,100
| +2% | +$128K | ﹤0.01% | 1388 |
|
|
2020
Q4 | $6.79M | Buy |
54,900
+600
| +1% | +$78.8K | ﹤0.01% | 1164 |
|
|
2020
Q3 | $5.29M | Buy |
54,300
+1,300
| +2% | +$162K | ﹤0.01% | 1147 |
|
|
2020
Q2 | $8.27M | Buy |
53,000
+10,900
| +26% | +$1.66M | 0.01% | 863 |
|
|
2020
Q1 | $6.08M | Buy |
42,100
+4,600
| +12% | +$888K | 0.01% | 833 |
|
|
2019
Q4 | $7.67M | Buy |
37,500
+800
| +2% | +$146K | 0.01% | 901 |
|
|
2019
Q3 | $2.95M | Buy |
36,700
+900
| +3% | +$76.4K | ﹤0.01% | 1436 |
|
|
2019
Q2 | $3.38M | Buy |
35,800
+800
| +2% | +$69.1K | ﹤0.01% | 1366 |
|
|
2019
Q1 | $2.99M | Buy |
35,000
+1,400
| +4% | +$116K | ﹤0.01% | 1399 |
|
|
2018
Q4 | $1.89M | Buy |
33,600
+400
| +1% | +$24.4K | ﹤0.01% | 1608 |
|
|
2018
Q3 | $2.71M | Buy |
33,200
+7,300
| +28% | +$514K | ﹤0.01% | 1509 |
|
|
2018
Q2 | $906K | Buy |
25,900
+6,000
| +30% | +$183K | ﹤0.01% | 2228 |
|
|
2018
Q1 | $408K | Hold |
19,900
| – | – | ﹤0.01% | 2425 |
|
|
2017
Q4 | $564K | Hold |
19,900
| – | – | ﹤0.01% | 2374 |
|
|
2017
Q3 | $619K | Buy |
19,900
+6,000
| +43% | +$180K | ﹤0.01% | 2302 |
|
|
2017
Q2 | $440K | Buy |
+13,900
| New | +$342K | ﹤0.01% | 2438 |
|
Other funds holding RETA
Swiss National Bank's RETA Position: Q3 2023 in Review
Swiss National Bank sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 52,400 shares — an estimated $5.34M sold.
Swiss National Bank first reported a position in RETA in Q2 2017 and held it in 25 quarters. The position peaked at $8.27M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Swiss National Bank reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Swiss National Bank sold 52,400 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $5.34M.
- Swiss National Bank first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2017 and held it in 25 quarters.
- Swiss National Bank's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $8.27M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Swiss National Bank's 13F filing for Q3 2023, filed 8 Nov 2023.